Journal of Medical Economics
Volume 23, 2020 - Issue 12
Hematology
Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv
, , & 
Ivo Abrahama Matrix45, Tucson, AZ, USA;c Cancer Center, University of Arizona, Tucson, AZ, USA;d Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA;e Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ, USA;f Department of Family and Community Medicine, College of Medicine, University of Arizona, Tucson, AZ, USACorrespondence[email protected]
https://orcid.org/0000-0003-0490-4421
https://orcid.org/0000-0003-0490-4421